^Matsuzawa-Yanagida K, Narita M, Nakajima M, et al. Usefulness of antidepressants for improving the neuropathic pain-like state and pain-induced anxiety through actions at different brain sites. Neuropsychopharmacology. July 2008, 33 (8): 1952–65. PMID 17957217. doi:10.1038/sj.npp.1301590.
^Koppert W, Wehrfritz A, Körber N, et al. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain. March 2004, 108 (1–2): 148–53. PMID 15109518. doi:10.1016/j.pain.2003.12.017.
^Stubhaug A, Romundstad L, Kaasa T, Breivik H. Methylprednisolone and Ketorolac rapidly reduce hyperalgesia around a skin burn injury and increase pressure pain thresholds. Acta Anaesthesiol Scand. October 2007, 51 (9): 1138–46. PMID 17714578. doi:10.1111/j.1399-6576.2007.01415.x.
^Warncke T, Stubhaug A, Jørum E. Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary Hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo.. Pain. August 1997, 72 (1–2): 99–106. PMID 9272793. doi:10.1016/S0304-3959(97)00006-7.
^De Kock MF, Lavand'homme PM. The clinical role of NMDA receptor antagonists for the treatment of postoperative pain. Best Pract Res Clin Anaesthesiol. March 2007, 21 (1): 85–98. PMID 17489221. doi:10.1016/j.bpa.2006.12.006.
^Klein T, Magerl W, Hanschmann A, Althaus M, Treede RD. Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic Hyperalgesia.. Eur J Pain. January 2008, 12 (1): 17–29. PMID 17449306. doi:10.1016/j.ejpain.2007.02.002.
^Christoph T, Kögel B, Strassburger W, Schug SA. Tramadol has a better potency ratio relative to morphine in neuropathic than in nociceptive pain models. Drugs in R&D. 2007, 8 (1): 51–57. PMID 17249849. doi:10.2165/00126839-200708010-00005.